Annovis Bio Inc is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, particularly conditions like Alzheimer's disease and Parkinson's disease. The company is dedicated to advancing its proprietary platform designed to target and modulate underlying pathologies associated with these diseases. Annovis Bio aims to improve patient outcomes by researching and delivering potential treatments that can enhance cognitive function and overall quality of life for individuals affected by debilitating neurological disorders.
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family
Annovis Bio shares rise in premarket trading on positive Phase III Parkinson's study results for buntanetap, showing cognitive improvements and stability compared to placebo.
Annovis announced new data from its Phase III Parkinson's study. The study showed improvements on the Unified Parkinson's Disease Rating Scale following treatment with Buntanetap.
Annovis Bio faces setbacks in Phase 2/3 Alzheimer's study, revealing minimal change in patients' conditions. Despite slight improvements in mild cases, results show no significant difference in treatment groups.
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.
